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Abstract
Background: Acupuncture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence
on effectiveness is limited. The purpose of the study was to evaluate the effectiveness of acupuncture for irritable
bowel syndrome in primary care when provided as an adjunct to usual care.
Methods: Design: A two-arm pragmatic randomised controlled trial.
Setting: Primary care in the United Kingdom.
Patients: 233 patients had irritable bowel syndrome with average duration of 13 years and score of at least 100 on
the IBS Symptom Severity Score (SSS).
Interventions: 116 patients were offered 10 weekly individualised acupuncture sessions plus usual care, 117 patients
continued with usual care alone.
Measurements: Primary outcome was the IBS SSS at three months, with outcome data collected every three
months to 12 months.
Results: There was a statistically significant difference between groups at three months favouring acupuncture with
a reduction in IBS Symptom Severity Score of −27.43 (95% CI: –48.66 to −6.21, p = 0.012). The number needed to
treat for successful treatment (≥50 point reduction in the IBS SSS) was six (95% CI: 3 to 17), based on 49% success
in the acupuncture group vs. 31% in the control group, a difference between groups of 18% (95% CI: 6% to 31%).
This benefit largely persisted at 6, 9 and 12 months.
Conclusions: Acupuncture for irritable bowel syndrome provided an additional benefit over usual care alone.
The magnitude of the effect was sustained over the longer term. Acupuncture should be considered as a treatment
option to be offered in primary care alongside other evidenced based treatments.
Trial Registration: Current Controlled Trials ISRCTN08827905
Keywords: Acupuncture, Irritable bowel syndrome, Randomised controlled trial, Primary care
Background
General practitioners [1] and patients [2] have expressed
their concerns regarding the adequacy and effectiveness
of current treatments for irritable bowel syndrome (IBS).
In a UK survey, 5% of patients receiving acupuncture
reported having consulted primarily for gastrointestinal
complaints, the most common being IBS [3]. However,
the evidence on acupuncture for IBS is weak. A
Cochrane review of six trials, with a median sample size
of 54, found insufficient evidence to determine if acu-
puncture is an effective treatment for IBS [4]. No evi-
dence of an acupuncture effect beyond placebo was
found in two subsequent trials which controlled for
non-specific effects [5,6].
Apart from three Chinese-based trials in the Cochrane
review, none of the above trials were designed to evalu-
ate the overall effect of acupuncture, i.e. an evaluation of
the combined specific effect of acupuncture and non-
specific effects associated with placebo. Moreover all of
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the trials delivered acupuncture in a way that the inter-
vention was constrained, such that acupuncturists were
not delivering acupuncture in a similar way to how they
would do so normally in routine care. None of the trials
were reported as based in primary care, instead they
were reported as based in hospital settings [5-11] or set-
tings were not reported [12,13]. Given this evidence gap,
and the uncertainty outlined in the Cochrane review,
further investigation of acupuncture for irritable bowel
syndrome is merited [4].
In this study we designed an open pragmatic rando-
mised controlled trial, in which we account for both the
temporal effects associated with any spontaneous recov-
ery and the effects of regression-to-the-mean, with the
aim of capturing the overall impact of acupuncture when
provided as a referral option in primary care. Our focus
on a primary care setting complements previous studies
conducted in secondary care [5-11]. We aimed to pro-
vide acupuncture as close as possible to how it would
normally be provided in routine care, with the incorpor-
ation of explanations and lifestyle advice based on acu-
puncture theory in a way that is integral to practice
[14,15]. This focus on acupuncture as a complex inter-
vention precludes the possibility of a feasible and valid
sham to control for all interacting components in a two-
arm trial [16,17]. Our design mirrors that used in a trial
of acupuncture for chronic low back pain which influ-
enced policy in the UK; the study was central to the
decision by the National Institute for Health and Clinical
Excellence (NICE) to recommend 10 sessions of acu-
puncture for persistent low back pain [18].
Based on this rationale, our research therefore aims
to provide practical comparative data on acupuncture
for irritable bowel syndrome that is relevant to primary
care and will be immediately applicable to patients and
providers. This design provides the evidence needed to
assist policy and decision-makers when considering acu-
puncture as a referral option for patients with irritable
bowel syndrome.
Methods
Design overview
Building on our pilot study (ISRCTN32823720) [19], we
conducted a parallel-arm randomised controlled trial to
determine the effectiveness of acupuncture plus usual
care compared to usual care alone for the treatment of
IBS based on a published protocol [20]. We received
ethics approval from the York NHS Research Ethics
Committee (08/H1311/66) in 2008. A cost-effectiveness
analysis is reported separately [21].
Settings and participants
We recruited patients from the databases of five gen-
eral practices. The GP practices identified potential
participants aged 18 or older who had consulted their
GP and been diagnosed with IBS, and coded accordingly
on the practice database. A letter was sent to all poten-
tially eligible participants, inviting them to complete a
baseline questionnaire and consent form and return
these to the York Trials Unit. We excluded patients who
did not speak English, who had a current diagnosis of
haemophilia, hepatitis, HIV, or were receiving cancer
care, had had major gastrointestinal surgery in the previ-
ous six months, were pregnant, had a history of psych-
osis or substance abuse, or were receiving acupuncture
at the time. Patients were recruited if they provided
informed consent and scored 100 or more on the IBS
Symptom Severity Score (SSS) [22].
Randomisation
We randomised participants equally to receive either a
short course of traditional acupuncture plus usual care
or usual care alone. The randomisation sequence was
computer generated at the University of York by an
independent data manager at the York Trials Unit, and
fully concealed from the research and administrative
staff who then informed participants of their allocation
by telephone and subsequently by letter.
Interventions
Nine professional acupuncturists provided the acupunc-
ture, and all were registered with the British Acupunc-
ture Council with at least three years’ post qualification
experience, and were working at independent clinics.
Their practice style was based on principles of Trad-
itional Chinese Medicine or “TCM”. Acupuncturists pro-
vided up to 10 sessions of acupuncture, adapted from a
previously tested protocol [19], which allowed explana-
tions and life-style advice based on acupuncture theory
and clinical judgement [16]. While actual selection
of points was individualised for patients and allowed
to change over time, there was standardisation of the
function of the acupuncture based on the theoretical
frameworks used, an approach proposed for maintain-
ing interventional integrity when delivering complex
interventions [23].
All patients remained under the care of their general
practitioner, and received usual care according to need.
We documented usual care, for both NHS and non-
NHS treatments, in both groups at three, six, nine and
12 months.
Outcomes and follow-up
Our primary outcome measure was the IBS Symptom
Severity Score (IBS SSS). This is scored from 0 to 500
(<75 = no IBS, 75–175 = “mild” case, 175–300 = “mod-
erate” and 300+ = “severe”), and it has been validated for
use in IBS patients [22]. Our primary end-point was at
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three months, with further follow-ups at six, nine and
12 months. We recorded participants’ baseline belief in
acupuncture, expectations that acupuncture might help
their IBS and treatment preferences.
Our secondary outcome measures were the IBS Non-
Colonic Symptom Score (which includes lethargy &
tiredness, “wind”, backache, and other symptoms [24],
and SF-12 to evaluate patients’ health related quality of
life [25]. EQ-5D was the primary outcome for the eco-
nomic study [26]. Outcomes at follow-up points were
sought by postal questionnaire, and where that failed to
elicit a response, the main outcome measure was sought
by telephone.
Statistical analysis
In our pilot study [19], we calculated that for a 50 point
difference on the IBS SSS, and an adjusted standard
deviation to be 105 points, we needed to recruit a
sample size of 94 patients per arm to have 90% power
and a significance level of 0.05. To allow for loss to fol-
low up of a similar proportion as observed in the pilot
at three months (13%), our trial required at least 220
patients. In the full-scale trial we used analysis of covari-
ance on an intention-to-treat basis to evaluate changes
between groups for the primary outcome of the IBS
SSS at three months, while adjusting for baseline scores
and general practice. The statistical analysis was con-
ducted using SAS version 9.2 and STATA version 10
using a 2-sided 5% significance level. We took a 50 point
improvement [22] or more on the IBS SSS between
baseline and three months as a “success” for our num-
ber-needed-to-treat analysis. We used similar analyses
to explore between-group differences on the IBS SSS at
other time points, and on secondary outcome measures.
We used linear regression to explore whether expectation,
belief and preference were treatment effect modifiers.
Results
Recruitment and follow-up of participants
The trial recruited patients from five general practices
(total list size of 53,666) between November 2008 and
June 2009. GP practices identified and invited 1,651
potentially eligible patients to participate. Of the 243
patients who responded with baseline documentation to
the York Trials Unit, 233 were recruited, see Flow Chart
in Figure 1. The average number recruited per general
practice was 47 (range 24 to 75).
Baseline characteristics
Patients’ mean age at baseline was 44, and 81% were
women, see Table 1 for full baseline details. The average
duration of their IBS was 13 years. In terms of potential
treatment effect modifiers, 56% believed acupuncture
worked, 29% expected that acupuncture would help their
IBS, 76% had a preference to be allocated to acupunc-
ture, and 39% received their preferred treatment option.
Acupuncture provision within the acupuncture arm of
the trial
There were seven female and two male acupuncture
practitioners with post-qualification experience ranging
from 3 to 25 years (mean 11). Practitioners provided
acupuncture for 113 patients, averaging 12 patients each
(range 3 to 22), covering 1016 treatments. The reasons
for patient non-attendance and discontinuation are pro-
vided in Figure 1. Patients received an average of 9 ses-
sions, with 88 patients (76%) receiving the full course,
and the average course of treatment was completed
within 12 weeks. Sessions were commonly 45 minutes
duration and provided at weekly intervals. In Table 2 we
provide a summary of the treatment details according to
the STRICTA requirements [27] and a full report is pub-
lished separately [28].
Usual care provision across both arms of the trial
We mapped the provision of usual care in both groups,
which was provided or purchased according to need,
and found differences in utilisation were minimal (see
Additional file 1). For example in the first three months
59/83 (69%) of patients in the acupuncture group con-
sulted at the their GP practice, compared to 72% of
patients in the usual care group, with patient consulting
on average 2.08 times and 2.25 times respectively, with
68% and 69% of these visits being related to IBS respect-
ively. Over the first three months, 65% of the acupunc-
ture group received prescription medication compared
to 61% of the usual care group, with antispasmodics
drugs, antidiarrhoeal drugs and laxatives making up a
relatively small proportion of this utilisation (Additional
file 1). Non-prescription medication was used by 58% in
the acupuncture group compared to 60% in the usual
care group.
Patient outcomes
Table 3 shows the results from the linear regression
model providing IBS Symptom Severity Scores at base-
line, 3, 6, 9 and 12 months, as illustrated in Figure 2.
The between-group comparison showed a statistically
significant reduction in symptoms in those allocated to
acupuncture at three months: –27.43 (95% CI: –48.66 to
−6.21, p = 0.012). The effect size could be described as
small to moderate (Cohen’s d = 0.36). Treatment was
assumed “successful” (≥50 points reduction on IBS SSS)
in 57/116 (49%) of patients in the acupuncture group
and 36/117 (31%) in those receiving usual care alone, a
difference of 18% (95% CI: 6% to 31%). The number
needed to treat was 6 (95% CI: 3 to 17), which means
that for roughly every 6 participants treated with
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acupuncture, you will see one participant with an
improvement equal to or greater than 50 in their base-
line IBS SSS score.
The difference on the IBS SSS scores between groups
subsequent to 3 months, adjusted for baseline, showed a
statistically significant reduction at 6 months [−22.59]
and 9 months [−27.0], followed by a near significant re-
duction at 12 months [−21.33], see Table 3 for confi-
dence intervals. We found that patient expectation and
belief were not treatment effect modifiers. Nor was
preference, whether on the basis of comparing groups
who preferred acupuncture vs. those who didn’t mind,
or when comparing those who got their preference vs.
those who did not. We found a statistically significant
reduction favouring the acupuncture group for the IBS
Non-Colonic Score only at three months, [−15.24 (95%
CI: –29.91 to −0.57)], but no significant differences in
the physical and mental component scores on the SF-12
at any time point (see Additional file 2).
Adverse events
No serious adverse events associated with acupuncture
were reported by acupuncturists in the logbooks or by
patients in follow-up questionnaires. Non-serious
adverse events associated with acupuncture were reported
by eleven patients: eight experienced pain from the
needles (three of the eight also reported nerve pain, bruis-
ing or fatigue), one had bruising from the needles, one
Excluded (n=10)
No consent form received 
(n= 5)
Not meeting inclusion criteria 
(n= 4 )
Declined to participate (n= 1)
Analysed (n=116)
Excluded from analysis (n=0),
Intention to Treat (ITT) (n=116)
Withdrawal from trial (n=3)
No reason given (1)
Feeling frail, acupuncture burdensome (1)
Death (1)
Response rates
At 3 months: 109 (94%)
At 6 months: 105 (91%)
At 9 months: 104 (90%)
At 12 months: 104 (90%)
Allocated to Acupuncture plus Usual 
Care (n=116)
Received acupuncture (n=113)
- Received 10 acupuncture sessions (n=88)
- Received < 10 acupuncture sessions (n=25)
Did not receive acupuncture (n=3)
Discontinued acupuncture (n=8)
Adverse event (1)
Change in life situation (2)
Felt uncomfortable / nervous (3)
Patient felt it was not working (1)
No IBS symptoms for 2 wks (1)
Received usual care (n=116)
Discontinued usual care (n=0)
Withdrawal from trial 
(n=7)
No reason given (3)
Uninterested as allocated to 
standard care - (3)
Full time carer - no time (1)
Response rates
At 3 months: 100 (85%)
At 6 months: 95 (81%)
At 9 months: 95 (81%)
At 12 months: 94 (80%)
Allocated to Usual Care 
alone (n=117)
Received usual care (n=117)
Discontinued usual care (n=0))
Analysed (n=117)
Excluded from analysis (n=0)
Intention to Treat (ITT) (n=117)
Allocation
Analysis
Follow-Up
Randomized (n=233)
Enrollment
Combined list size 
of general medical 
practices targeted 
(n=53,666)
Identified patients 
(n=1,651)
Assessed for eligibility 
(n=243)
Figure 1 CONSORT flow diagram.
MacPherson et al. BMC Gastroenterology 2012, 12:150 Page 4 of 10
http://www.biomedcentral.com/1471-230X/12/150
had a slight burn from a moxibustion stick, and one
had itchy and swollen skin where one of the needles had
been inserted.
Discussion
Summary of main findings
For patients with chronic irritable bowel syndrome,
our study showed that acupuncture provided as an
adjunct in primary care is associated with a small yet
statistically significant clinical reduction in symptoms
at three months. This was reflected in 49% of patients
in the acupuncture group and 31% in the usual care
group improving by more than 50 points in their IBS
SSS score, with six being the number-needed-to-treat.
This effect was largely sustained through to 12 months.
We also found acupuncture for this group of patients
had a high level of acceptability, as shown by the will-
ingness by patients to attend for acupuncture once they
had commenced treatment, completing on average
9 out of the 10 weekly acupuncture sessions that were
available.
Strengths and limitations
This study is the first pragmatic randomised controlled
trial of acupuncture for IBS in primary care. The design
ensured that we controlled for temporal effects associated
Table 1 Baseline patient characteristics
Characteristic Acupuncture (n = 116) Usual care (n = 117) Overall (n = 233)
Age
Mean (SD) 44.28 (14.31) 42.68 (14.79) 43.47 (14.54)
Median (min to max) 43.81 (21.33 to 78.29) 42.00 (19.51 to 74.47) 42.69 (19.51 to 78.29)
Gender
Male, n (%) 21 (18.10) 24 (20.51) 45 (19.31)
Education (full time)
Yes (%) 5 (4.31) 4 (3.42) 9 (3.86)
Work (full time) (n = 90) (n = 81) (n = 171)
Yes (%) 57 (49.14) 63 (53.85) 120 (51.50)
Work (Not full time) (n = 54) (n = 51) (n = 105)
Work part-time 31 (26.72) 19 (16.24) 50 (21.16)
Currently looking for work 1 (0.86) 4 (3.42) 5 (2.15)
Permanently unable to work 4 (3.45) 0 (0.00) 4 (1.72)
Looking after home/family 4 (3.45) 10 (8.55) 14 (6.01)
Retired 11 (9.48) 16 (13.68) 27 (11.59)
Other 3 (2.59) 2 (1.71) 5 (2.15)
Belief: In general, do you think acupuncture can work?
Yes (%) 61 (52.59) 69 (58.97) 130 (55.79)
No (%) 1 (0.86) 0 (0.00) 1 (0.43)
Don’t know (%) 54 (46.55) 48 (41.03) 102 (43.78)
Expectation: Do you think acupuncture may help your IBS?
Yes (%) 31 (26.72) 37 (31.62) 68 (29.18)
No (%) 1 (0.86) 1 (0.85) 2 (0.86)
Don’t know (%) 84 (72.41) 79 (67.52) 163 (69.96)
Preference 1: Which treatment do you prefer?
Acupuncture (%) 90 (77.59) 88 (75.21) 178 (76.39)
Standard care (%) 0 (0.00) 1 (0.85) 1 (0.43)
Don’t mind either (%) 26 (22.41) 28 (23.93) 54 (23.18)
Preference 2: Did you get your treatment preference?
Got what I preferred (%) 90 (77.59) 1 (0.85) 91 (39.06)
Did not get what I preferred (%) 0 (0.00) 88 (75.21) 88 (37.77)
Did not have preference (%) 26 (22.41) 28 (23.93) 54 (23.18)
Irritable Bowel Syndrome Symptom Severity Score (IBS SSS):
Mean (SD) 280.00 (81.34) 277.17 (71.50) 278.59 (76.47)
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with spontaneous recovery and regression-to-mean effects
associated with having a minimum cut-off on our IBS SSS
scale. The trial had an adequate sample size, and was
conducted rigorously at all stages, with unambiguously
concealed allocation to prevent subversion of the
randomisation. Of the 1,651 potentially eligible patients
identified by GP practices that were invited to participate,
243 patients responded, a rate that is typical of trials in
primary care that use a database method for recruitment.
We used validated outcomes measures, with response
rates at 3, 6, 9 and 12 months that were reasonably high,
at over 80 per cent in the control group and over 90 per
cent in the intervention group. We have documented that
there was reasonable equivalence in usual care received in
both groups at three months, which leads us to cautiously
ascribe any differences between groups to the treatment
provided by acupuncturists. We explored the impact of
variables that are potentially associated with placebo
effects, namely patients’ beliefs, expectations and treat-
ment preferences [29], but they were not found to be
treatment effect modifiers.
There is likely to be a contribution to the overall
benefit we observed due to the additional attention
received in the acupuncture group resulting from the
contact time with practitioners in the acupuncture
arm. We did not control for this bias, which would
have required a trial arm with a practitioner-led inter-
vention in order to control for time and attention.
The patients in our study were not blind to their
group allocation, as would have been the case in a
sham-controlled trial. A comparator trial arm with a
sham control would have had the limitation that the
verum acupuncture would need to be constrained to
minimise variability in patient experience between the
verum and sham acupuncture arms. There is a trade-
off between seeking to know more about the contri-
bution each of the components might (or might not)
contribute to any putative benefit and seeking to
know more about the impact of acupuncture as a
package of care that more closely reflects routine
practice. A third trial arm was outside of the scope of
our funding support.
Table 2 Details of the acupuncture treatment in items structured according to the STRICTA [27] reporting guidelines,
an official extension to CONSORT
STRICTA item Details of acupuncture treatment within the trial
1. a) Style Traditional Chinese Medicine (TCM).
b) Reasoning for treatment provided Systematic review by Lim [4] and pragmatic design to evaluate acupuncture as provided in routine care.
c) Variation Individualized treatments using common TCM theoretical frameworks: primarily zang-fu syndromes
(used with 99% of patients), and also qi, blood and body fluids, eight principles, five elements, and external
pathogenic factors.
2. a) Number of needles per treatment On average 14 needles were inserted per session (range: 4 – 23) using an average of seven point locations
(range 5 to 9).
b) Names 126 different points were used. A common core of points, LI 4, LR 3, ST 36, SP 6, were used in over 50%
of treatments.
c) Depth of insertion Average depth was 1.5 cm (range: 0.2 – 5 cm).
d) Response sought The response sought varied, most commonly de qi.
e) Needle stimulation Manual.
f) Retention Average 20 min (range: few seconds to 30 min).
g) Needle type Most common length was 25 mm (range: 15–40 mm) and diameter 0.20 mm (range: 0.30 to 0.16 mm).
3. a) Number of sessions Patients were offered 10 sessions and completed an average of 9 sessions.
b) Frequency & duration Usually once a week over 12 weeks.
4. a) Other components of treatment Acupuncturists were allowed to use cupping, moxa, brief tui-na, brief acupressure, breathing, and ear seeds.
The most commonly used was moxa (used with 13% of patients), brief tui na (9%) and brief acupressure
(6%). Herbs & magnets were prohibited. Acupuncturists were allowed to provide lifestyle advice as part of
the patient’s treatment consistent with their routine practice, with a restriction against probiotics. In total
68% of patients received lifestyle advice, most commonly diet (56%), stress reduction and relaxation (24%)
and exercise (6%).
b) Setting and context Provision or treatments in independent clinics. Acupuncturists encouraged to practice as closely as possible
as they normally would.
5. Participating acupuncturists British Acupuncture Council members, with more than three years post-qualification experience.
Predominant treatment style: Traditional Chinese Medicine.
6. Control or comparator interventions Patients in both groups continued to receive their usual care from their general practitioner, as well as
over-the-counter treatments according to need. This allowed us to evaluate the impact of acupuncture as
an adjunct to usual care. A summary of usual care actually received in both arms are provided in the
main text.
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Table 3 Results of linear regression models fitted at each separate time point on the IBS Symptom Severity Score
Variable Baseline Mean (SD) Month 3 (95% CI) Month 6 (95% CI) Month 9 (95% CI) Month 12 (95% CI)
Primary analysis: IBS Symptom Severity Score
Acupuncture group 280.00 (81.34) 213.78 (199.31 to 228.25) 201.60 (186.08 to 217.12) 206.40 (190.39 to 222.41) 209.79 (194.56 to 225.03)
Usual care group 277.17 (71.50) 241.21 (225.69 to 256.73) 224.19 (207.91 to 240.48) 233.40 (217.21 to 249.59) 231.12 (214.81 to 247.44)
Between group differences in means (acupuncture-usual care) - −27.43 (−48.66 to −6.21) −22.59 (−45.11 to −0.08) −27.00 (−49.77 to −4.23) −21.33 (−43.66 to 1.00)
At each time point, predicted means and their 95% confidence intervals from the fitted model are presented except at baseline where the raw means and their standard deviation are presented.
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The study population was made up of those who
have consulted with predominantly “moderate” IBS
symptoms in primary care (average IBS SSS score of
279), have experienced these symptoms for an average
of 13 years and have not experienced sufficient symp-
tom reduction from their usual care so that they are
continuing to seek care. Therefore generalising the
results to patients who are consulting their GP for
the first time, and who therefore have not experi-
enced usual GP care and its impact on symptoms,
must be done with caution. The trial was not pow-
ered to determine whether any of the sub-groupings
of patients with IBS symptoms (for example based on
severity) would have fared better or worse.
Comparison with existing studies
Our study had the longest duration in terms of collect-
ing outcome data through to 12 months after random-
isation. By contrast, most other studies have been
conducted within hospital based settings, with more nar-
rowly defined populations, smaller sample sizes and
shorter term follow-ups [4]. The level of acceptability of
acupuncture treatments among patients was high (only
three patients out of 116 did not start treatment and
88 (76%) completed their full course of treatment, with
an overall average of nine sessions attended out of 10)
compared to a trial of cognitive behavioural therapy for
IBS in which fewer than half of patients were considered
by the therapist to have completed therapy, with 41%
either declining therapy or dropping out [30].
Components of acupuncture are drawn from three
categories: needling related components; non-needling
components that are acupuncture-specific, such as
explanations and lifestyle advice; and non-specific com-
ponents that are generic to the therapeutic encounter,
such as the patient-practitioner relationship [31]. Our
trial is unique in that it was designed to include the sec-
ond of these components, as well as the other two.
However it was not designed to determine the extent to
which each of these components of acupuncture con-
tributed to the overall outcome. To establish a propor-
tional contribution of a component of treatment would
require a trial arm with a sham control, for example as
has been done recently to explore the impact of the
patient-practitioner relationship [10]. In their trial, sham
acupuncture needling was used to control for the need-
ling in verum acupuncture arm, which then allowed
the impact of a variation in the intensity of patient-
practitioner relationship to be measured. By contrast,
our focus on acupuncture as a complex intervention
with many interacting components meant that a feasible
and valid sham control was problematic [16,17].
With regard to placebo effects among patients with
IBS, there is some limited evidence from other studies
that these effects appear to tail off after three months,
according to a study that reviewed 27 randomised con-
trolled trials of treatments for IBS, with individual trials
showing no placebo response at 12 months [32]. The
results from our trial, in contrast, provide some evidence
of a sustained effect at 12 months.
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Implications for future research and clinical practice
Our trial focussed on those patients with long term
symptoms at recruitment (average 13 years duration)
for whom usual GP care was of limited benefit; how-
ever, exploring the potential impact of referral to acu-
puncture soon after an initial diagnosis of IBS would
be useful. An appropriately powered study could de-
termine whether any of the sub-groupings of patients
with IBS symptoms (for example based on mild, mod-
erate or severe categories) fared better or worse, and
also characterize responders and non-responders to
acupuncture. A clearer specification of optimal acu-
puncture treatment for this group of patients would
be helpful. In particular it would be useful to deter-
mine if more than 10 acupuncture sessions would im-
prove outcomes, as from the graph in Figure 2 the
steep improvement of the acupuncture group appears
to level off quite abruptly when treatment ceases. To
separate out the impact of different components of
treatment, a sham controlled trial design similar to
that used by Kaptchuk and colleagues [10] could be
used to determine whether or not the provision of
explanations and life-style advice might (or might
not) add to any overall effect, assuming that effects of
different treatment components are additive rather
than synergistic.
There is a need for a number of effective options for
treatment in primary care, given the frustration experi-
enced by some patients with existing treatments [2].
Our results showed that, on average, acupuncture is
associated with a small to moderate reduction in symp-
toms in a population that has had IBS symptoms for
many years. If a patient responds at three months, then
this benefit is likely on average to be sustained at 12
months. The IBS Symptom Severity Score is now widely
used in IBS research and has been translated into many
languages. When used in assessing response to treat-
ment, a reduction of 50 points is regarded as clin-
ically significant and, therefore, a reduction of 70 points
after 12 months in a group of primary care patients
in whom symptoms have been refractory, suggests that
this is a treatment option worth considering in such
individuals, especially as the beneficial effects seem to
be sustained. These data on acupuncture are highly rele-
vant to the primary care context in the UK and have
policy implications.
Conclusion
In a rigorously conducted pragmatic randomised con-
trolled trial, we have evaluated the effectiveness of acu-
puncture as a treatment for irritable bowel syndrome
when offered as an adjunct to usual treatment in pri-
mary care. Acupuncture was found to significantly
improve outcomes at three months, with the number
needed to treat being six. We found some evidence of a
sustained benefit over the longer term. Acupuncture
should be considered as a potential treatment option in
primary care alongside other evidence-based treatments.
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